Cargando…

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy

BACKGROUND: YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a secreted glycoprotein produced by various cell types including stromal, immune, and cancer cells. It contributes to cancer progression through tumor-promoting inflammation and has been shown to inhibit the cytotoxicity of T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansen, Astrid Z., Novitski, Sif I., Hjaltelin, Jessica X., Theile, Susann, Boisen, Mogens K., Brunak, Søren, Madsen, Daniel H., Nielsen, Dorte L., Chen, Inna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513102/ https://www.ncbi.nlm.nih.gov/pubmed/37744345 http://dx.doi.org/10.3389/fimmu.2023.1228907

Ejemplares similares

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis
por: Holmstroem, Rikke Boedker, et al.
Publicado: (2022)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records
por: Hjaltelin, Jessica Xin, et al.
Publicado: (2023)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2021)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection
por: Hedetoft, Morten, et al.
Publicado: (2021)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

YKL-40 as a possible marker of neutrophilic asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2023)

YKL-40 and the Cellular Metabolic Profile in Parkinson’s Disease
por: Gevezova, Maria, et al.
Publicado: (2023)

YKL-40 and genetic status of CHI3L1 in a large group of asthmatics
por: Hansen, Jakob W., et al.
Publicado: (2015)

Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol
por: Spindler, Nicklas Juel, et al.
Publicado: (2023)

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer
por: Schultz, Nicolai A., et al.
Publicado: (2013)

YKL-40, a secreted glycoprotein, promotes tumor angiogenesis
por: Shao, Rong, et al.
Publicado: (2009)

YKL-40 acts as an angiogenic factor to promote tumor angiogenesis
por: Shao, Rong
Publicado: (2013)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Effect of Vitamin D on YKL-40: Rat Hypercholesterolemia Model
por: Kocabas, Rahim
Publicado: (2023)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer
por: Kim, Steve H, et al.
Publicado: (2007)

YKL-40 levels are independently associated with albuminuria in type 2 diabetes
por: Røndbjerg, Anne K, et al.
Publicado: (2011)

Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension
por: Wang, Dong, et al.
Publicado: (2012)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

CTX-II and YKL-40 in early diagnosis and treatment evaluation of osteoarthritis
por: Wang, Pengkun, et al.
Publicado: (2019)

Serum YKL-40 levels and disease characteristics in patients with rheumatoid arthritis
por: Jafari-Nakhjavani, Mohammad Reza, et al.
Publicado: (2019)

Circulatory YKL-40 & NLR: Underestimated Prognostic Indicators in Diffuse Glioma
por: Gandhi, Puneet, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9c6kt9i5n1kku4dk38dh2uore2